Found vs MEDVi vs SkinnyRx (2026)
On tirzepatide, the order is Found ($289) → SkinnyRx↗ ($299) → MEDVi↗ ($399) — gaps of $10 and then $100 a month, a $1,320 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
The three records, one screen
Found: the record, condensed
On tirzepatide, the number that matters at Found is $289 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes Found unusually easy to compare and unusually easy to leave.
Context for that figure: it ranks #6 of 17 in the verified tirzepatide index — $74/month above the floor (NexLife↗, $215) — and sits $160 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,468.
Found’s semaglutide program bills $289 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.
The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.
To place the number: #15 of 20 verified programs, with the floor $156/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $60 a month. A year at this figure: $3,468 monthly-billed.
Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗
SkinnyRx: the record, condensed
Start with the load-bearing figure: $299 a month, all-in, is what SkinnyRx charges for tirzepatide at the 10 mg basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes SkinnyRx unusually easy to compare and unusually easy to leave.
Context for that figure: it ranks #7 of 17 in the verified tirzepatide index — $84/month above the floor (NexLife, $215) — and sits $150 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,588.
On semaglutide, the number that matters at SkinnyRx is $199 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.
The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.
To place the number: #11 of 20 verified programs, with the floor $66/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $150 a month. A year at this figure: $2,388 monthly-billed.
Operationally at SkinnyRx: shipping included; commitment none; cancellation no membership on compounded programs; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the SkinnyRx page · visit SkinnyRx ↗
MEDVi: the record, condensed
Start with the load-bearing figure: $399 a month, all-in, is what MEDVi charges for tirzepatide at the 10 mg basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $399 is the whole subscription, which makes MEDVi unusually easy to compare and unusually easy to leave.
To place the number: #14 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.
On semaglutide, the number that matters at MEDVi is $299 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.
There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.
Context for that figure: it ranks #18 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.
Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗
Prices, gaps, and what sits inside them
Found holds the low ground at $289 — dose-flat, so that figure is a ceiling with no membership attached. SkinnyRx follows at $299 (+$10/mo, $120/yr). MEDVi tops the trio at $399 (+$110/mo over the leader, $1,320/yr) — note its record’s watch-out below.
The semaglutide picture reshuffles the order: SkinnyRx $199 → Found $289 → MEDVi $299 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.
Who wins what
Cheapest month-to-month: Found ($289); cheapest 12-month path: Found ($3,468); cheapest semaglutide of the three: SkinnyRx ($199).
Every winner above is a computation, not a placement; the pairwise pages carry the full duels: Found vs SkinnyRx · Found vs MEDVi · SkinnyRx vs MEDVi.
Everything besides the three prices
Memberships: Found none; SkinnyRx none; MEDVi none. Structures: Found dose-flat; SkinnyRx dose-flat; MEDVi dose-flat. Pharmacies: Found not named; SkinnyRx not named; MEDVi not named. States: Found — most states; SkinnyRx — not published; MEDVi — priced differently in CA/NC on some plans. Exit terms: Found — membership recurs; prepaid terms are paid up front; SkinnyRx — no membership on compounded programs; MEDVi — 12-month plan applies to lowest rate.
The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: Found third-party reported (2026-08-05); SkinnyRx source-verified (2026-08-05); MEDVi source-verified (2026-08-05).
The trio on semaglutide, across time
3 mo: SkinnyRx $597 vs Found $867 vs MEDVi $897 6 mo: SkinnyRx $1,194 vs Found $1,734 vs MEDVi $1,794 12 mo: SkinnyRx $2,388 vs Found $3,468 vs MEDVi $3,588 — monthly-billed totals; prepaid paths where published appear on each provider page.
The trio, annualized
Found: $3,468/yr monthly-billed; SkinnyRx: $3,588/yr monthly-billed; MEDVi: $4,788/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $2,640 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.
The elimination read
Work it as eliminations rather than a beauty contest. MEDVi enters owing an explanation: $110/month above Found compounds to $1,320 a year — real therapy-months of money — so its record has to name what the premium buys (structure the cheaper two lack) or it exits first. SkinnyRx survives the first cut only to face the harder question — whether nothing structural — its case is purely situational is worth $10 a month to you — because a middle option that cannot answer it is just the expensive option with better camouflage. Found is what remains: the arithmetic answer at $289, dethroned only by a state gap, a structural need, or a prescriber’s judgment — the three things this page deliberately cannot decide.
The same trio on best published rate: Found $289 → SkinnyRx $299 → MEDVi $399 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — Found $867, SkinnyRx $897, MEDVi $1,197; 6 months — Found $1,734, SkinnyRx $1,794, MEDVi $2,394. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.
Grade the three records before trusting the three prices. On the five-point disclosure checklist (price, pharmacy, states, cancellation, source-verification): Found 3/5 · SkinnyRx 4/5 · MEDVi 4/5. The gap between SkinnyRx (4/5) and Found (3/5) is itself information: undisclosed axes are where the questions in each provider’s review earn their keep. No axis splits them, a small collective credit. Every score is a computation from the dataset, contestable at the corrections desk like any other figure.
The three-way verdict compresses cleanly: Found is the default on arithmetic; SkinnyRx earns the middle only where its structure (flat pricing) solves something the floor does not; and MEDVi’s $110/month premium over the leader — $1,320 a year, roughly 4.6 extra months of therapy at the floor rate — needs a named justification from its record, not a vibe. Insurance coverage, where it exists, outranks all three.
Frequently asked
Which is cheapest: Found, MEDVi, or SkinnyRx?
Found, at $289/month all-in tirzepatide — $10 under SkinnyRx and $110 under MEDVi; on semaglutide the cheapest of the three is SkinnyRx at $199. Captured 2026-08-09.
Which of the three is best over a full year?
Found’s best path prices twelve months at $3,468; monthly-billed years run Found $3,468, SkinnyRx $3,588, MEDVi $4,788.
Are these rankings paid or editorial?
Neither — they are sorts of the public dataset on the all-in maintenance basis, regenerated on every data change; the methodology page defines the basis and the JSON lets you recompute every figure here.